R-Pharm US LLC was established in 2014 by Mark Pavao and Demetrios Kydonieus with the goal of building the US commercialization business for R-Pharm JSC.
Based in Princeton, NJ, R-Pharm US LLC is focused on acquiring and commercializing underserved pharmaceutical brands in both the oncology and chronic autoimmune therapeutic areas.
On July 1, R-Pharm US completed the purchase of Ixempra from Bristol Myers Squibb. The plan is to establish a sales force and build commercial muscle and lay the groundwork for the future launches of innovative products currently in development and pharmaceutical brands acquired.